253 related articles for article (PubMed ID: 27914766)
1. Histomorphological changes in endometriosis in a patient treated with ulipristal: A case report.
Bateman J; Bougie O; Singh S; Islam S
Pathol Res Pract; 2017 Jan; 213(1):79-81. PubMed ID: 27914766
[TBL] [Abstract][Full Text] [Related]
2. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
Donnez J; Donnez O; Dolmans MM
Expert Opin Drug Saf; 2016 Dec; 15(12):1679-1686. PubMed ID: 27740868
[TBL] [Abstract][Full Text] [Related]
3. Endometrial Changes in Surgical Specimens of Perimenopausal Patients Treated With Ulipristal Acetate for Uterine Leiomyomas.
Nogales FF; Crespo-Lora V; Cruz-Viruel N; Chamorro-Santos C; Bergeron C
Int J Gynecol Pathol; 2018 Nov; 37(6):575-580. PubMed ID: 28914672
[TBL] [Abstract][Full Text] [Related]
4. Endometrial Effects of Prolonged Therapy with the Selective Progesterone Receptor Modulator Ulipristal Acetate: A Case Report.
Levy G; Elkas J; Armstrong AY; Nieman LK
J Reprod Med; 2016; 61(3-4):159-62. PubMed ID: 27172639
[TBL] [Abstract][Full Text] [Related]
5. The endometrial response to modulation of ligand-progesterone receptor pathways is reversible.
Chodankar RR; Murray A; Nicol M; Whitaker LHR; Williams ARW; Critchley HOD
Fertil Steril; 2021 Sep; 116(3):882-895. PubMed ID: 33865567
[TBL] [Abstract][Full Text] [Related]
6. Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator.
Ioffe OB; Zaino RJ; Mutter GL
Mod Pathol; 2009 Mar; 22(3):450-9. PubMed ID: 19136935
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of progesterone receptor modulators and their effect on the endometrium.
Spitz IM
Curr Opin Obstet Gynecol; 2009 Aug; 21(4):318-24. PubMed ID: 19602929
[TBL] [Abstract][Full Text] [Related]
8. Selective progesterone receptor modulators.
Whitaker LH; Williams AR; Critchley HO
Curr Opin Obstet Gynecol; 2014 Aug; 26(4):237-42. PubMed ID: 24950125
[TBL] [Abstract][Full Text] [Related]
9. Ulipristal acetate for uterine fibroid-related symptoms.
Puchar A; Luton D; Koskas M
Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
[TBL] [Abstract][Full Text] [Related]
10. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
Szamatowicz M; Kotarski J
Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
[TBL] [Abstract][Full Text] [Related]
11. Sonographic and hysteroscopic endometrial examination in women treated with ulipristal acetate: Exploratory findings at a tertiary referral center.
Gracia M; Nonell R; Ros C; Rius M; Quintas L; Martínez-Zamora MÁ; Carmona F
Eur J Obstet Gynecol Reprod Biol; 2019 Jan; 232():40-45. PubMed ID: 30468982
[TBL] [Abstract][Full Text] [Related]
12. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
Pérez-López FR
Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
[TBL] [Abstract][Full Text] [Related]
13. Pathologic Changes in Uterine Leiomyomas After Extended Treatment With Ulipristal Acetate.
Chang MC; Latta E
Int J Gynecol Pathol; 2020 Mar; 39(2):146-151. PubMed ID: 30702466
[TBL] [Abstract][Full Text] [Related]
14. [Ulipristal acetate (Esmya): a selective modulator of progesterone receptors, new treatment of uterine fibromatosis].
Nisolle M; Closon F; Firquet A; Top M; Pintiaux A
Rev Med Liege; 2014 Apr; 69(4):220-5. PubMed ID: 24923103
[TBL] [Abstract][Full Text] [Related]
15. [Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology].
Brazert M; Korman MP; Pawelczyk LA
Ginekol Pol; 2013 Sep; 84(9):794-800. PubMed ID: 24191519
[TBL] [Abstract][Full Text] [Related]
16. Ulipristal Acetate Prior to Surgery for Endometriosis.
Singh SS; Evans D; McDonald S; Senterman M; Strickland S
Reprod Sci; 2020 Sep; 27(9):1707-1714. PubMed ID: 32006245
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment of uterine fibroids with ulipristal acetate ☆.
Donnez J; Vázquez F; Tomaszewski J; Nouri K; Bouchard P; Fauser BC; Barlow DH; Palacios S; Donnez O; Bestel E; Osterloh I; Loumaye E;
Fertil Steril; 2014 Jun; 101(6):1565-73.e1-18. PubMed ID: 24630081
[TBL] [Abstract][Full Text] [Related]
18. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
Williams AR; Bergeron C; Barlow DH; Ferenczy A
Int J Gynecol Pathol; 2012 Nov; 31(6):556-69. PubMed ID: 23018219
[TBL] [Abstract][Full Text] [Related]
19. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
Talaulikar VS; Manyonda I
Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
[TBL] [Abstract][Full Text] [Related]
20. Endometrial changes during ulipristal acetate use: A systematic review.
De Milliano I; Van Hattum D; Ket JCF; Huirne JAF; Hehenkamp WJK
Eur J Obstet Gynecol Reprod Biol; 2017 Jul; 214():56-64. PubMed ID: 28482329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]